Which has grown faster, ALT or NEO?

Over the past five years, NEO grew revenue faster — ALT at a -65.38% CAGR versus NEO at 9.41%.

How have ALT and NEO total returns compared?

Over the past 5 years, ALT delivered -25.30% and NEO delivered -15.14% annualized total return. Past performance doesn't predict future results.

Altimmune, Inc. (ALT) vs NeoGenomics, Inc. (NEO)

A side-by-side comparison of Altimmune, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ALT

Altimmune, Inc.

$519M

$2.67HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

NEO

NeoGenomics, Inc.

$492M

$19.13HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ALT vs NEO

growth of $100 · dividends reinvested · last 9y

ALT -98.0% (-35.2%/yr)NEO +162.9% (+11.3%/yr)NEO compounded faster over this window

Log scale — wide-divergence pair

ALT NEO

ALT vs NEO: by the numbers

•ALT is the larger company ($519M vs $492M market cap).
•Both run net losses; NEO's is the smaller (-6.77% vs -296000.00% net margin).
•NEO grew revenue faster over the past five years (9.41% vs -65.38% CAGR).

Metrics side by side

Valuation

Metric	ALT	NEO
Forward P/E	N/A	104.69
P/S ratio	16749.86	0.64
P/B ratio	1.09	0.63

Profitability

Metric	ALT	NEO
Gross margin	100.00%	42.92%
Operating margin	-230460.98%	-8.63%
Net margin	-296000.00%	-6.77%
ROE	-19.35%	-6.60%
ROIC	-19.47%	-5.29%

Growth (annualized)

Metric	ALT	NEO
Revenue CAGR (5Y)	-65.38%	9.41%
Total return CAGR (5Y)	-25.30%	-15.14%

Frequently asked

Which has grown faster, ALT or NEO?: Over the past five years, NEO grew revenue faster — ALT at a -65.38% CAGR versus NEO at 9.41%.
How have ALT and NEO total returns compared?: Over the past 5 years, ALT delivered -25.30% and NEO delivered -15.14% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALT analysis Full NEO analysis Interactive comparison tool

Dig into the metrics

Altimmune ROE NeoGenomics ROE Altimmune operating margin NeoGenomics operating margin Altimmune revenue growth NeoGenomics revenue growth Altimmune free cash flow NeoGenomics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.